Pharmaceutical Cannabis - CIS

Revenue in the 0 market in CIS is forecasted to reach 0.00 in 2024.
The revenue is anticipated to demonstrate an annual growth rate (CAGR 2024-0.00) of [globalrevenue_currentlayer_yeartoday_currentcountryvalue], culminating in a market volume of 0.00 by [globalrevenue_currentlayer_yeartoday_currentcountryvalue].
When compared globally, the majority of revenue will originate from 0 ([globalrevenue_currentlayer_yeartoday_maxcountrynameprep] in 2024).
In terms of per capita figures, 0.00 in revenue is generated per person in 2024.
The pharmaceutical cannabis market in the CIS region is rapidly expanding with increased research and investment opportunities.

Key regions: United States, Spain, Europe, Thailand, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceutical Cannabis market in CIS is experiencing a notable growth trajectory driven by changing customer preferences, emerging trends, local special circumstances, and underlying macroeconomic factors.

Customer preferences: Customers in the CIS region are increasingly showing a preference for pharmaceutical cannabis products due to growing awareness about the potential health benefits associated with these products. The shift towards natural and alternative remedies is influencing consumer choices, leading to a rise in demand for pharmaceutical cannabis.

Trends in the market: In the CIS region, there is a noticeable trend towards the legalization and regulation of pharmaceutical cannabis for medical purposes. This trend is opening up new opportunities for market players to enter the industry and cater to the growing demand for cannabis-based pharmaceutical products. Additionally, there is a rising trend of research and development activities focused on exploring the therapeutic properties of cannabis, further fueling market growth.

Local special circumstances: The CIS region presents unique circumstances that are shaping the pharmaceutical cannabis market. Despite facing regulatory challenges and cultural stigmas associated with cannabis, several countries in the region are gradually moving towards legalizing medical cannabis. This shift is creating a favorable environment for market development and attracting investments from both domestic and international players.

Underlying macroeconomic factors: The economic landscape in the CIS region is also playing a significant role in the development of the pharmaceutical cannabis market. Economic growth, government initiatives to boost the healthcare sector, and increasing healthcare expenditure are contributing to the expansion of the pharmaceutical cannabis market. Moreover, changing regulatory frameworks and evolving consumer preferences are influencing market dynamics in the region.

Methodology

Data coverage:

Data encompasses B2B and B2C enterprises. Figures are based on companies' revenues, funding values and global consumer survey data. Revenues include retail, sales and taxes.

Modeling approach / Market size:

Market sizes are determined by a Top-Down approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports, third-party data. Next, we use relevant key market indicators and data from country-specific associations such as tobacco spending per capita, medical product spending per capita, consumer spending and consumer spending for recreation purposes, population. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.